Twist Bioscience 8-K

PositiveEarningsGuidance raisedImpairment / chargeLegal / investigation

DNA Synthesis and Protein Solutions leads growth; FY2026 revenue outlook raised and Q4 adjusted EBITDA breakeven reaffirmed.

Filed 2026-05-04 07:21 ET

Summary

Q2 FY2026 results with raised FY2026 revenue guidance. Revenue reached a record $110.7M, up 19% Y/Y and marking a 13th consecutive quarter of sequential growth; both business segments grew. Twist raised its FY2026 revenue range and reiterated Q4 FY2026 adjusted EBITDA breakeven.

Key Figures

Metric Q2 FY2026 Q2 FY2025 Y/Y
Revenue $110.7M $92.8M 19.3%
Operating loss $(45.9)M $(41.6)M n/m
Net loss $(44.0)M $(39.3)M n/m
Diluted EPS $(0.71) $(0.66) n/m
Adjusted EBITDA, non-GAAP $(13.3)M $(14.8)M n/m
  • DNA Synthesis and Protein Solutions revenue rose 28% Y/Y to $53.3M, up 4% Q/Q; NGS Applications revenue rose 12% Y/Y to $57.4M, up 9% Q/Q.
  • Gross margin increased to 51.6% from 49.6%, a 200 bp improvement. The $7.2M litigation settlement cost, net of recoveries, was included in GAAP results and excluded from adjusted EBITDA; the company reached a settlement in principle of ≈$17.1M in a securities class action.
  • Cash, cash equivalents and short-term investments totaled ≈$172M at 3/31/2026. Adjusted EBITDA improved from $(14.8)M to $(13.3)M.

Guidance

Metric Period Guidance Prior Direction
Total revenue FY2026 $442M-$447M; growth of 17%-19% $435M-$440M Raised
Gross margin FY2026 Above 52% — —
Total revenue Q3 FY2026 ≈$114M-$115M; ≈19% Y/Y growth at midpoint — —
Adjusted EBITDA, non-GAAP Q4 FY2026 Breakeven — Reaffirmed

Investor Takeaways

  • Q3 revenue and NGS-led sequential growth will indicate whether the company is tracking toward its stated return to 20% NGS growth by Q4.
  • FY2026 gross margin above 52% and Q4 adjusted EBITDA breakeven are the company’s stated profitability milestones.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback